Managing Peptide Inventory in a Medical Weight Loss Clinic
Plan clinic inventory by presentation, calculate reorder points, rotate stock by usable expiry, and document receiving exceptions without over-ordering.
For facility-specific purchasing requirements, visit our medical weight loss clinics sourcing guide. This article covers procurement, not treatment protocols.
Track exact presentations separately
Create a separate inventory record for each approved formulation, concentration, and package size. Record source, lot, expiry or beyond-use date, storage conditions, usable quantity, and location. Do not aggregate unlike vials into a single stock count.
Use demand and lead time together
A practical reorder point is expected consumption during replenishment lead time plus a justified safety buffer. Base consumption on actual use and clinician-reviewed scheduled demand. Count quarantined or expired units as unavailable, not as stock that can cover appointments.
Work a simple planning example
For inventory planning only: if an approved presentation uses 12 sealed units per week, confirmed lead time is two weeks, and the clinic chooses a six-unit buffer, the reorder point is 30 usable units. If 20 usable units are on hand and 10 are confirmed inbound, the inventory position is 30. This is not a dosing or prescribing example.
Cap orders at usable shelf life
A reorder calculation is not permission to buy more than the practice can use before expiry or beyond-use dating. Rotate by earliest usable expiry and keep open-container limits distinct from unopened dating. Confirm labeling requirements with the responsible clinician or pharmacist.
Reconcile receipts and holds
Match each delivery to its purchase order and log damage, shortages, missing documents, and temperature concerns. Quarantine questionable units and record who authorizes release or disposition. Perform regular physical counts against the ledger.
Plan for supply changes without automatic substitutions
Maintain an escalation process for backorders and regulatory changes. Do not replace a preparation simply because another is advertised as similar. See the post-shortage sourcing guide; this inventory method does not establish eligibility for compounded GLP-1 products.
What to do next
Record unresolved questions and the evidence your clinical or quality reviewer needs before ordering. Use the medical weight loss clinics purchasing page to prepare a facility-specific inquiry. Product mentions do not confirm stock, a legal supply pathway, or suitability for patient care.
Regulatory sources and purchasing limits
Compounded drugs are not FDA-approved. Facility registration does not establish approval or eligibility for every preparation. Verify the exact product, source, applicable federal requirements, and state rules before ordering. This is procurement education, not medical or legal advice.
- FDA: bulk substances used under section 503B, including restrictions and interim policies.
- FDA: GLP-1 compounding and shortage updates.
- FDA: safety concerns for certain compounding substances.